S100A9 and plasma cell myeloma: The lack of such differences in previously reported results could be explained by insufficient purity of isolated populations of myeloid cells or distinct features of the 5T33 multiple myeloma model (perhaps also explaining the lack of significant antitumor effect of blocking S100A9 with ABR-238901 in that study).